Analysts/Institutional Investor Meet/Con. Call Updates

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000 E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 June 25, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra-Kurla Complex, Dalal Street, Fort, Bandra (East), Mumbai – 400 001 Mumbai – 400 051 Scrip code: 512529 Symbol: VIYASH Subject: Submission of Investor Day presentation Dear Sir/ Madam, Pursuant to our intimation dated June 17, 2026, and in accordance with Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the presentation to be made at “Viyash Investor Day – 2026”, scheduled for today i.e. June 25, 2026, at Mumbai. The aforesaid presentation is also being made available on the website of the Company at: www.viyash.com You are requested to take the same on record. Yours faithfully, For Viyash Scientific Limited (Formerly Sequent Scientific Limited) Yoshita Vora Company Secretary & Compliance Officer Encl. Viyash Scientific INVESTOR DAY VIYASH MANAGEMENT TEAM June 2026 © 2026 Viyash Scientific Ltd. All Rights Reserved. 1 Agenda Section 01 Welcome Section 02 Our journey Our strengths Section 03 Section 04 Business snapshot Section 05 Growth drivers Section 06 Our aspiration © 2026 Viyash Scientific Ltd. All Rights Reserved. 2 WELCOME ©© 22002266 VViiyyaasshh SScciieennttiiffiicc LLttdd.. AAllll RRiigghhttss RReesseerrvveedd.. 33 About our MD & CEO Dr. Haribabu Bodepudi is the MD & Group CEO of Viyash Scientific Limited since Dec 2025 Dr. Hari has 30 years of extensive experience in the pharmaceutical industry, prior to being appointed as the Group CEO, Dr. Hari was the CEO of Viyash Life Sciences, which he promoted alongside Dr. Sri Hari in 2019 Under his leadership, Viyash Life Sciences acquired Symed and Appco before merging with Sequent Scientific last year Prior to starting Viyash Life Sciences, Dr. Hari spent ~20 years with Mylan laboratories where he held several leadership roles including being the CEO of Mylan India and Global COO of Mylan He was responsible for 50+ facilities at Mylan managing a large portfolio of 200+ APIs and 15,000 formulation SKUs Dr. Haribabu Dr. Hari has a hands-on experience in global supply chain, regulatory, API R&D, quality and commercial operations Bodepudi He has played a pivotal role in integrating the two companies and creating a platform which is now set to become a leading MD & Group CEO integrated pharmaceutical platform with capabilities across front-end, backend, for both human and animal health 1993 2000-2019 2019-2024 2024-2025 2026 Onwards Long way to go ahead – Has grand aspirations to transform Viyash into a leading integrated Completed PhD in 20 years at Mylan – Founded Viyash Life Played a pivotal pharmaceuticals company Organic Chemistry CEO of Mylan India Sciences and drove role in Sequent - from Andhra and Global COO of Symed and Appco Viyash merger University Mylan acquisitions © 2026 Viyash Scientific Ltd. All Rights Reserved. 44 OUR JOURNEY AND MISSION ©© 22002266 VViiyyaasshh SScciieennttiiffiicc LLttdd.. AAllll RRiigghhttss RReesseerrvveedd.. 55 Who we are? We are an integrated pharmaceutical platform across animal and human health backed by science and IP IP and Global presence Backward Front end Strong technology across animal integrated presence in management driven company and human capabilities key markets team with health global experience © 2026 Viyash Scientific Ltd. All Rights Reserved. 66 Our Journey Viyash Life Sciences Foundation & Early Growth Scale & Expansion Integration & Global Reach Founded in February 2019 by Acquisition of Mylan's API and Unified manufacturing operations, Dr Haribabu Bodepudi. formulation units in Vizag and Mumbai. expanded R&D to over 200 scientists, filed Strategic investment by the Carlyle Group. 175+ patents*, and strengthened global Rapid expansion through acquisitions partnerships and regulatory capabilities. of Vindhya Pharma and Vandana Life Acquisition of Symed Labs and Appco Sciences, and establishment of API Pharma LLC, strengthening global capabilities R&D infrastructure. Scientific Limited 2025 onwards Foundation & Evolution Global Expansion Specialization & Growth 1985–2013 2014–2019 2020–2025 Originated as Visistha Trades, Established Alivira as a dedicated Focused on new geographies transitioned into a focused animal health brand. Expanded and specialized animal pharmaceutical and animal operations across Europe, Latin healthcare segments, building a health company, and rebranded America, and emerging markets with strong global manufacturing as SeQuent Scientific Limited. USFDA veterinary API approvals. and distribution network. SeQuent Scientific © 2026 Viyash Scientific Ltd. All Rights Reserved. (*) Cumulative patents filed since acquisition of Symed Labs 77 Both businesses have had their own individual strengths Sequent Scientific Limited Viyash Life Sciences Strong frontend Only USFDA Strong Backward integrated presence in large approved API manufacturing to intermediates animal health markets facility for animal and R&D setup providing cost - Europe, Emerging health in India with 9 USFDA competitiveness market and India approved sites Global manufacturing Diverse product IP driven US based (Europe, LATAM portfolio company manufacturing and India) presence for FDF API supplier to top Presence in Diverse product pharma innovators 150+ countries portfolio Niche API capabilities © 2026 Viyash Scientific Ltd. All Rights Reserved. 88 STRENGTHS OF THE COMBINATION ©© 22002266 VViiyyaasshh SScciieennttiiffiicc LLttdd.. AAllll RRiigghhttss RReesseerrvveedd.. 99 Management Team Ramakant Singani AVV Srinivas (Group CFO) (SVP – R&D Head) Rajaram Narayanan Rajkamal Varshney (CEO – Animal Health) (SVP – Head of BD) Dr AJ Reddy (SVP – Head of SCM) Alexis Goux BN Srinivas (COO – Animal Health) (Regulatory and Quality) Yoshita Vora (Company Secretary) Dr. Peddanna G Srinivas Muncheti (COO - Appco) (VP – Human Resources) DR. HARIBABU BODEPUDI MD & Group CEO Sameer Pandit Harveen Jindal (CCO - Appco) (Head of R&D – Animal Health) © 2026 Viyash Scientific Ltd. All Rights Reserved. 10 16 world class manufacturing facilities Turkey Spain MANUFACTURING SITES Brazil I India – AH Formulations Brazil II API Formulations © 2026 Viyash Scientific Ltd. All Rights Reserved. 11 API manufacturing capabilities Site Capabilities Regulatory Approvals USFDA/ EU-GMP/ PMDA/ TGA/ Viyash Scientific Unit I (Viyash -1) API / HP API KFDA/ WHO-GMP USFDA/ EU-GMP/ Viyash Scientific Unit II (Viyash -2) API/ HP API WHO-GMP/ANVISA USFDA/ EU-GMP/ WHO-GMP / Viyash Scientific Unit III (Symed -1) API KFDA/ ANVISA/NIP HUGARY Viyash Scientific Unit IV (Symed -IV) API USFDA/ EU-GMP/ WHO-GMP USFDA/ COFEPRIS/ EU-GMP / Viyash Scientific Unit V (Symed -II) API KFDA/ ANVISA/NIP HUGARY USFDA for Advanced API + Advanced Viyash Scientific Unit VI (Symed -VI) Intermediates/ ANVISA for API/ Intermediates WHO-GMP USFDA for Viyash Scientific Unit VII (SV Labs) Advanced Intermediates Advanced Intermediates USFDA for Viyash Scientific Unit VIII (VOPL) Advanced Intermediates Advanced Intermediates Viyash Scientific Unit IX (AH) API EU-GMP/ COFEPRIS Mexico (Mahad) Alivira Vizag API US FDA/ WHO-Geneva © 2026 Viyash Scientific Ltd. All Rights Reserved. 1122 Formulations manufacturing sites Site Type of formulation Regulatory Approvals Turkey Animal EU GMP/ Turkish GMP Brazil Unit I Animal Brazil GMP Brazil Unit II Animal Brazil GMP India Animal WHO-Geneva Spain Animal EU GMP/ Turkish GMP USA Human USFDA © 2026 Viyash Scientific Ltd. All Rights Reserved. 1133 Formulations manufacturing capabi [Showing first 8,000 characters — download PDF for full document]